SYNCOMF

Syncom Formulation (India) Share Price

₹19.78 -0.35 (-1.74%)

21 Nov, 2024 14:20

SIP TrendupStart SIP in SYNCOMF

Start SIP

Performance

  • Low
  • ₹20
  • High
  • ₹20
  • 52 Week Low
  • ₹10
  • 52 Week High
  • ₹28
  • Open Price₹20
  • Previous Close₹20
  • Volume2,399,019

Investment Returns

  • Over 1 Month -3.55%
  • Over 3 Month + 21.93%
  • Over 6 Month + 46.17%
  • Over 1 Year + 101.11%
SIP Lightning

Smart Investing Starts Here Start SIP with Syncom Formulation (India) for Steady Growth!

Invest Now

Syncom Formulation (India) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 56.1
  • PEG Ratio
  • 1.4
  • Market Cap Cr
  • 1,859
  • P/B Ratio
  • 6.5
  • Average True Range
  • 1.12
  • EPS
  • 0.35
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.11
  • RSI
  • 47.45
  • MFI
  • 57.03

Syncom Formulation (India) Financials

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹19.78
-0.35 (-1.74%)
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹20.47
  • 50 Day
  • ₹20.33
  • 100 Day
  • ₹19.05
  • 200 Day
  • ₹16.83

Resistance and Support

20.36 Pivot Speed
  • R3 21.65
  • R2 21.30
  • R1 20.71
  • S1 19.77
  • S2 19.42
  • S3 18.83

What's your outlook on Syncom Formulation (India)?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Syncom Formulations Ltd. manufactures pharmaceutical products, including tablets, capsules, syrups, and ointments. Serving both domestic and international markets, it offers a broad range of affordable, high-quality medicines across therapeutic segments like antibiotics, pain relief, and vitamins.

Syncom Formulations India has an operating revenue of Rs. 329.28 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 25% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 80 which is a GOOD score indicating consistency in earnings, a RS Rating of 82 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Syncom Formulation (India) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-17 Audited Results
2024-02-14 Quarterly Results
2023-11-08 Quarterly Results

Syncom Formulation (India) F&O

Syncom Formulation (India) Shareholding Pattern

50.57%
0%
0.1%
45.15%
4.18%

About Syncom Formulation (India)

  • NSE Symbol
  • SYNCOMF
  • BSE Symbol
  • 524470
  • Managing Director
  • Mr. Vijay Shankarlal Bankda
  • ISIN
  • INE312C01025

Similar Stocks to Syncom Formulation (India)

Syncom Formulation (India) FAQs

Syncom Formulation (India) share price is ₹19 As on 21 November, 2024 | 14:06

The Market Cap of Syncom Formulation (India) is ₹1859.3 Cr As on 21 November, 2024 | 14:06

The P/E ratio of Syncom Formulation (India) is 56.1 As on 21 November, 2024 | 14:06

The PB ratio of Syncom Formulation (India) is 6.5 As on 21 November, 2024 | 14:06

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23